N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats

被引:57
作者
Chen, N. [1 ]
Aleksa, K. [2 ]
Woodland, C. [2 ,3 ]
Rieder, M. [1 ,4 ,5 ]
Koren, G. [1 ,2 ,3 ,4 ,6 ]
机构
[1] Univ Western Ontario, Dept Physiol & Pharmacol, Ivy Chair Mol Toxicol, London, ON N6A 5C1, Canada
[2] Hosp Sick Children, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada
[3] Univ Toronto, Fac Med, Dept Pharmacol, Toronto, ON, Canada
[4] Univ Western Ontario, Dept Paediat, London, ON N6A 5C1, Canada
[5] Childrens Hosp Western Ontario, CIHR GSK Chair Paediat Clin Pharmacol, London, ON, Canada
[6] Univ Western Ontario, Schulich Sch Med & Dent, Ivy Chair Mol Toxicol, London, ON N6A 5C1, Canada
关键词
ifosfamide; N-acetylcysteine; nephrotoxicity; glutathione; lipid peroxidation; glutathione S-transferase; histological changes;
D O I
10.1038/bjp.2008.15
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and purpose: Ifosfamide nephrotoxicity is a serious adverse effect for children undergoing cancer chemotherapy. Our recent in vitro studies have shown that the antioxidant N-acetylcysteine (NAC), which is used extensively as an antidote for paracetamol ( acetaminophen) poisoning in children, protects renal tubular cells from ifosfamide-induced toxicity at a clinically relevant concentration. To further validate this observation, an animal model of ifosfamide-induced nephrotoxicity was used to determine the protective effect of NAC. Experimental approach: Male Wistar albino rats were injected intraperitoneally with saline, ifosfamide ( 50 or 80 mg kg(-1) daily for 5 days), NAC ( 1.2 g kg(-1) daily for 6 days) or ifosfamide+NAC ( for 6 days). Twenty-four hours after the last injection, rats were killed and serum and urine were collected for biochemical analysis. Kidney tissues were obtained for analysis of glutathione, glutathione S-transferase and lipid peroxide levels as well as histology analysis. Key results: NAC markedly reduces the severity of renal dysfunction induced by ifosfamide with a significant decrease in elevations of serum creatinine ( 57.8 +/- 2.3 vs 45.25 +/- 2.1 mmol l(-1)) as well as a reduced elevation of beta(2)-microglobulin excretion ( 25.44 +/- 3.3 vs 8.83 +/- 1.3 nmol l(-1)) and magnesium excretion ( 19.5 +/- 1.5 vs 11.16 +/- 1.5 mmol l(-1)). Moreover, NAC significantly improved the ifosfamide-induced glutathione depletion and the decrease of glutathione S-transferase activity, lowered the elevation of lipid peroxides and prevented typical morphological damages in renal tubules and glomeruli. Conclusions and implications: Our results suggest a potential therapeutic role for NAC in paediatric patients in preventing ifosfamide nephrotoxicity.
引用
收藏
页码:1364 / 1372
页数:9
相关论文
共 49 条
[1]   Prevention and Treatment of Contrast-Induced Nephropathy [J].
Al-Ghonaim, Mohammed ;
Pannu, Neesh .
TECHNIQUES IN VASCULAR AND INTERVENTIONAL RADIOLOGY, 2006, 9 (02) :42-49
[2]   A tubule cell model for ifosfamide nephrotoxicity [J].
Aleksa, K ;
Halachmi, N ;
Ito, S ;
Koren, G .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2005, 83 (06) :499-508
[3]   Efforts to establish an animal model of Fanconi syndrome after ifosfamide administration to rats [J].
Appenroth, D. ;
Werner, T. ;
Lupp, A. ;
Patzer, L. ;
Misselwitz, J. ;
Fleck, C. .
JOURNAL OF APPLIED TOXICOLOGY, 2007, 27 (04) :327-336
[4]  
Badary OA, 1999, EXP NEPHROL, V7, P323
[5]   Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice [J].
Badary, OA .
JOURNAL OF ETHNOPHARMACOLOGY, 1999, 67 (02) :135-142
[6]  
Badary OA, 1998, ONCOL RES, V10, P355
[7]  
BENVENUTO JA, 1992, NACETYLCYSTEINE ANTI, V3, P19
[8]   The effect of N-acetylcysteine on ifosfamide-induced nephrotoxicity:: in vitro studies in renal tubular cells [J].
Chen, Nancy ;
Aleksa, Katarina ;
Woodland, Cindy ;
Rieder, Michael ;
Koren, Gideon .
TRANSLATIONAL RESEARCH, 2007, 150 (01) :51-57
[9]  
DEVRIES N, 1993, J CELL BIOCHEM, P270
[10]   Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels [J].
Dickey, DT ;
Wu, YJ ;
Muldoon, LL ;
Neuwelt, EA .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 314 (03) :1052-1058